With the introduction of novel monoclonal antibody products into the clinic, significant new strategies are being developed to improve upon existing treatment for non-Hodgkin's lymphoma.
Methods
Monoclonal antibodies are being used alone, in combination with chemotherapy, or as adjuncts to autologous bone marrow transplantation for the purpose of purging bone marrow of neoplastic cells.
Results
Monoclonal antibodies when used in vivo in conjunction with autologous bone marrow transplantation have been relatively well tolerated. Results from several trials seem to demonstrate a therapeutic benefit for the use of such combinations.
Conclusions
Before these agents can be included in standard bone marrow transplantation regimen, long-term survival outcomes need to be obtained from randomized trials. We review the results from recent trials using monoclonal antibodies in conjunction with autologous stem cell transplantation for the treatment of non-Hodgkin's lymphoma.
References
1.
KohlerG., MilsteinC.. Continuous cultures of fused cells secreting antibody of predefined specificity.Nature.1975; 256: 495–497.
2.
NadlerL.M., StashenkoP., HardyR.. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen.Cancer Res.1980; 40: 3147–3154.
3.
PressO.W., AppelbaumF., LedbetterJ.A.. Monoclonal anti-body1F5 (anti-CD20) serotherapy of human B cell lymphomas.Blood.1987; 69: 584–591.
4.
LubeckM.D., SteplewskiZ., BagliaF.. The interaction of murine IgG subclass proteins with human monocyte Fc receptors.J Immunol.1985; 135: 1299–1304.
5.
PhilipT., ChauvinF., ArmitageJ.. Parma international protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation.Blood.1991; 77: 1587–1592.
6.
GuglielmiC., GomezF., PhilipT.. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial.J Clin Oncol.1998; 16: 3264–3269.
7.
GribbenJ.G., FreedmanA.S., NeubergD.. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma.N Engl J Med.1991; 325: 1525–1533.
8.
FreedmanA.S., NeubergD., MauchP.. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma.Blood.1999; 94: 3325–3333.
9.
DyerM.J., KelseyS.M., MackayH.J.. In vivo “purging” of residual disease in CLL with Campath-1H.Br J Haematol.1997; 97: 669–672.
10.
HaleG., XiaM.Q., TigheH.P.. The CAMPATH-1 antigen (CDw52).Tissue Antigens.1990; 35: 118–127.
11.
BucksteinR., ImrieK., SpanerD.. Consolidative immunotherapy with Rituxan in autologous stem cell transplants for follicular lymphoma is associated with molecular remissions.Proc Annu Meet Am Soc Clin Oncol.2000; 94. Abstract.
12.
FlinnI.W., O'DonnellP.V., GoodrichA.. Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.Biol Blood Marrow Transplant.2000; 6: 628–632.
13.
MagniM., Di NicolaM., DevizziL.. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion.Blood.2000; 96: 864–869.
14.
FlinnI.W., JonesR.J., GoodrichA.. Rituximab during autologous stem cell transplantation for lymphoma produces lymphoma free grafts in most patients by PCR and clonogenic assays.Blood.2001; 2832. Abstract.
15.
VosoM.T., PantelG., WeisM.. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma.Br J Haematol.2000; 109: 729–735.
16.
HorwitzS.M., BreslinS., NegrinR.S.. Rituximab following high dose chemotherapy and autografting in B-cell non-Hodgkin's lymphoma (NHL): preliminary results of a phase III trial.Proc Annu Meet Am Soc Clin Oncol.2000; 195. Abstract.
17.
BucksteinR.J., RimrieK., PennellN.. Prolonged molecular and clinical remission after treatment of a patient with follicular lymphoma with rituximab.Leuk Lymphoma.2001; 41: 451–455.
18.
van OosterhoutY.V., van den Herik-OudijkI.E., WesselsH.M.. Effect of isotype on internalization and cytotoxicity of CD19-ricin A immunotoxins.Cancer Res.1994; 54: 3527–3532.
KaminskiM.S., EstesJ., ZasadnyK.R.. Radioimunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience.Blood.2000; 96: 1259–1266.
21.
PressO.W., EaryJ.F., AppelbaumF.R.. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support.N Engl J Med.1993; 329: 1219–1224.
22.
PressO.W., Eary JF AppelbaumF.R.. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.Lancet.1995; 346: 336–340.
23.
PressO.W., EaryJ.F., GooleyT.. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas.Blood.2000; 96: 2934–2942.
24.
VoseJ.M., BiermanP.J., LynchJ.C.. Radioimmunotherapy with Bexxar combined with high-dose chemotherapy (HDC) followed by autologous hematopoietic stem cell transplantation (ASCT) for refractory non-Hodgkin's lymphoma (NHL): synergistic results with no added toxicity.Proc Annu Meet Am Soc Clin Oncol.2001; 19. Abstract.
25.
VriesendorpH.M., HerpstJ.M., GermackM.A.. Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01.J Clin Oncol.1991; 9: 918–928.
26.
WinterJ.N., InwardsD., ErwinW.. Phase I trial combining 90Y Zevalin and high-dose BEAM chemotherapy with hematopoietic progenitor cell transplant in relapsed or refractory B-cell NHL.Proc Am Soc Hem.2001; 2835. Abstract.
27.
BiermanP.J., VoseJ.M., LeichnerP.K.. Yttrium 90-labeled antiferritin followed by high-dose chemotherapy and autologous bone marrow transplantation for poor-prognosis Hodgkin's disease.J Clin Oncol.1993; 11: 698–703.
